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Immunogenic cell death (ICD) is a type of cancer cell death triggered by
certain chemotherapeutic drugs, oncolytic viruses, physicochemical thera-
pies, photodynamic therapy, and radiotherapy. It involves the activation of
the immune system against cancer in immunocompetent hosts. ICD com-
prises the release of damage-associated molecular patterns (DAMPs) from
dying tumor cells that result in the activation of tumor-specific immune
responses, thus eliciting long-term efficacy of anticancer drugs by combin-
ing direct cancer cell killing and antitumor immunity. Remarkably, subcu-
taneous injection of dying tumor cells undergoing ICD has been shown to
provoke anticancer vaccine effects in vivo. DAMPs include the cell surface
exposure of calreticulin (CRT) and heat-shock proteins (HSP70 and
HSP90), extracellular release of adenosine triphosphate (ATP), high-mobil-
ity group box-1 (HMGB1), type I IFNs and members of the IL-1 cytokine
family. In this review, we discuss the cell death modalities connected to
ICD, the DAMPs exposed during ICD, and the mechanism by which they
activate the immune system. Finally, we discuss the therapeutic potential
and challenges of harnessing ICD in cancer immunotherapy.
1. Introduction
Immunogenic cell death (ICD) is a form of regulated
cell death (RCD) that is sufficient to activate an adap-
tive immune response in an immunocompetent setting
[1]. It has been classified as a distinct poorly defined
entity induced by certain chemotherapeutic drugs,
oncolytic viruses, physicochemical therapies, photody-
namic therapy, and radiotherapy [1,2]. Recently,
Legrand et al. proposed to define ICD on the basis of
the communication between dying and immune cells as
a successful dialog between a dying cell and an
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appropriately disposed immune system [3]. Neverthe-
less, the molecular mechanisms of this interaction are
yet to be defined. The long-standing idea that the
immune system functions by merely making a distinc-
tion between self and non-self has been revised with the
introduction of the danger model that posits a model in
which our immune system responds to entities that
cause damage as opposed to those that are simply for-
eign [4]. Dying or stressed cells release molecules that
can function as either adjuvants or danger signals for
the immune system. These signals are collectively called
damage-associated molecular patterns (DAMPs) [5].
Importantly, ICD encompasses the release of DAMPs
from dying tumor cells, that are recognized by innate
pattern recognition receptors (PRRs), such as Toll-like
receptors (TLRs) and NOD-like receptors (NLRs)
resulting in the activation of tumor-specific immune
responses, thus provoking long-term efficacy of anti-
cancer drugs by combining direct cancer cell killing and
antitumor immunity, generally associated with immuno-
logical memory [1,2]. Herein, we discuss different stim-
uli of ICD, the role of DAMPs in T-cell cross-priming,
and the activation of antitumor immune response.
Finally, we discuss future perspectives for therapeutic
targeting of ICD in cancer therapy.
2. Immunogenicity of cell death
pathways
Accumulating evidence has shown that dying cells
actively regulate immune responses as they release or
expose molecules that serve as danger signals to stimu-
late the innate immune system. Nonetheless, the inter-
action between cell death trigger and the downstream
molecular pathways that determines cell death
immunogenicity is highly complex [3,6]. Here, we dis-
cuss the cell death pathways commonly described to
induce an immune response, focusing on apoptosis,
necroptosis, and pyroptosis (Fig. 1). Other cell death
modalities are extensively reviewed elsewhere [1].
2.1. Apoptosis
Apoptosis is a form of RCD important for develop-
ment, tissue homeostasis, and immunity [7]. During
apoptosis, cells undergo cytoplasmic shrinkage, nuclear
fragmentation, chromatin condensation, and plasma
membrane blebbing followed by the formation of
apoptotic bodies that are efficiently and rapidly cleared
by phagocytes [8–10]. Apoptosis is mediated by the
activity of caspase proteases and can be engaged by
two modes: intrinsic and extrinsic, both converge upon
activation of caspase-3 and caspase-7 (Fig. 1) [11].
Intrinsic apoptosis is triggered by perturbation in the
environment involving DNA damage, endoplasmic
reticulum (ER) stress, excessive reactive oxygen species
(ROS) formation, and replication stress. The key event
for intrinsic apoptosis is mitochondrial outer mem-
brane permeabilization (MOMP) [11], that is regulated
by the interactions between the pro-apoptotic and the
anti-apoptotic B-cell lymphoma 2 (BCL-2) family
members [12]. The pro-apoptotic proteins BCL-2-asso-
ciated X (BAX) and BCL-2 homologous antagonist
killer (BAK) permeabilize the mitochondrial outer
membrane; subsequently, cytochrome c and other sol-
uble proteins are released from the mitochondrial
intermembrane space resulting in caspase activation
and cell death (Fig. 1) [11].
Extrinsic apoptosis is engaged following binding of
death ligands including FAS ligand (FASL), tumor
necrosis factor (TNF), or TNF-related apoptosis-in-
ducing ligand (TRAIL) to their cognate receptors,
FAS, TNFRSF1A, and TNFRSF10A and
TNFRSF10B receptors, respectively [3]. FAS and
TRAIL induce the assembly of the death-inducing sig-
naling complex (DISC), whereas TNF ligation induces
complex I and complex II. These complexes function
as a platform to regulate caspase-8 activation [1]. The
DISC is composed of FAS-associated protein with
death domain (FADD), caspase-8, and cellular
FLICE-like inhibitory protein (c-FLIP) [3]. In contrast
to FAS and TRAIL, the primary signaling output of
TNF is not death but rather cell survival via complex
I that induces the activation of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-jB) and
mitogen-activated protein kinase (MAPK). This ulti-
mately leads to the production of inflammatory cytoki-
nes and prosurvival proteins such as c-FLIP. The
receptor-interacting serine/threonine protein kinase 1
(RIPK1) is a key signaling molecule that actively
determines the balance between inflammation and cell
survival, apoptosis, and necroptosis, a form of cas-
pase-independent RCD (Fig. 1) [13]. TNF-induced cell
death is tightly regulated by several checkpoints. Upon
removal of these brakes, complex II is formed com-
prising RIPK1, FADD, caspase-8, and c-FLIP. For-
mation of complex II leads to the activation of
caspase-8 that activates caspase-3 and caspase-7 and
mediates the crosstalk between intrinsic apoptosis and
extrinsic apoptosis by cleaving pro-apoptotic BH3
interacting domain death agonist (BID). The active
truncated form of BID (tBID) then activates BAX and
BAK and effectively triggers MOMP (Fig. 1) [13].
Although MOMP is critical for intrinsic apoptosis,
caspases are not, as typically cells die post-MOMP in
the absence of caspase activity. Caspases appear to
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function primarily to accelerate cell death—this serves
important functions during development and keeps
apoptosis immunologically silent [14–17]. For example,
apoptotic caspases cleave and inactivate cyclic GMP-
AMP synthase (cGAS) and interferon regulatory fac-
tor 3 (IRF3) to suppress type I interferon (IFN)
response [18]. Caspases also inactivate DAMPs indi-
rectly such as high-mobility group box-1 (HMGB1)
[19]. Thus, engaging MOMP while blocking caspases
strongly provokes ICD through the activation of NF-
jB and the induction of mitochondrial DNA
(mtDNA)-mediated type I IFN responses [14,16,17]. In
line with this, caspase inhibition has been shown to
induce antitumor activities accompanied by tumor
regression [14]. Furthermore, emricasan, a pan caspase
inhibitor, synergizes with radiation and the immune
checkpoint inhibitor, anti-programmed death ligand
(PD-L1), to induce systemic antitumor effects [20].
Fig. 1. Overview of necroptosis, apoptosis, and pyroptosis signaling pathways. Binding of death ligands such as tumor necrosis factor (TNF)
to their cognate receptor (TNFR) leads to pleiotropic signaling including inflammation and cell survival, apoptosis, and necroptosis,
determined by the key signaling molecule, the receptor-interacting serine/threonine protein kinase 1 (RIPK1). Upon inhibition of caspase-8,
RIPK1 activates RIPK3 leading to the formation of the necrosome. The necrosome then phosphorylates and activates mixed-lineage kinase-
like (MLKL) that causes rapid membrane permeabilization and necroptosis. Activation of caspase-8 leads to activation of caspase-3 and
caspase-7 and cell death (extrinsic apoptosis). The intrinsic apoptosis pathway is initiated by perturbation in the internal environment
including DNA damage that causes mitochondrial outer membrane permeabilization (MOMP). MOMP is regulated by the interaction
between pro-apoptotic and anti-apoptotic B-cell lymphoma 2 (BCL-2) family proteins. The pro-apoptotic proteins BCL-2 associated X (BAX)
and BCL-2 homologous antagonist killer (BAK) form pores at the mitochondrial outer membrane leading to the subsequent release of
cytochrome c and the formation of the APAF-1 apoptosome. The apoptosome activates caspase-9, which subsequently activates caspase-3
and caspase-7 resulting in apoptosis. Caspase-8 mediates the crosstalk between the intrinsic and extrinsic apoptosis pathways by cleaving
the pro-apoptotic BH3-interacting domain death (BID) to truncated BID (tBID) that activates BAX and BAK. Damage-associated molecular
patterns (DAMPs) released from dying cells activate pattern recognition receptors such as Toll-like receptors (TLR). This leads to the
activation of canonical inflammasomes that activate caspase-1. Active caspase-1 cleaves gasdermin D (GSDMD) liberating an N-terminal
(GSDMDNT) pore-forming fragment from the C-terminal (GSDMDC) inhibitory fragment. GSDMDNT form pores leading to membrane
permeabilization and pyroptosis. Active caspase-1 also cleaves the pro-inflammatory cytokines interleukin 1b (IL-1b) and IL-18 into their
mature form that are released by GSDMD pores.
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While most of anticancer therapies induce apoptosis,
only a few do so in immunogenic way [21]. Those
include anthracyclines [22], oxaliplatin, oncolytic
viruses, radiotherapy, and photodynamic therapy
[2,23]. Such therapies are proposed to act by inducing
the release of DAMPs in addition to cell death [1].
Remarkably, subcutaneous injection of cancer cells
treated with the aforementioned therapies induces a
potent cancer vaccine effect [5,23,24].
2.2. Necroptosis
Necroptosis is a lytic form of RCD that requires the
activation of the kinases RIPK1 and RIPK3, which
assemble into the necrosome. Necroptosis is initiated
by death receptors including TNF, PRRs such as
TLR3 that sense viral nucleic acids, TLR4 detecting
bacterial lipopolysaccharide (LPS), and the activation
of the intracellular sensor Z-DNA-binding protein,
ZBP (also known as DAI), that senses cytoplasmic
viral proteins. Necroptosis downstream TNF signaling
requires inhibition of caspase-8 in complex II resulting
in the activation of RIPK3 by RIPK1 [13,21,25,26].
Once activated, RIPK3 phosphorylates mixed-lineage
kinase-like (MLKL) leading to its oligomerization at
the plasma membrane, causing rapid membrane per-
meabilization (Fig. 1) and the subsequent release of
immunogenic DAMPs that robustly activate the innate
and adaptive immune systems [25,27,28].
In contrast to apoptotic and lytic necrotic cells,
necroptotic dying cells mediate DAMP release,
increase antigen uptake by phagocytes, and induce
dendritic cell (DC) maturation leading to efficient
CD8+ T-cell cross-priming, a functional outcome of
antigen cross-presentation, whereby antigen-specific
na€ıve CD8+ T cells are activated to become cytotoxic
T lymphocytes, and antitumor immunity. These effects
require RIPK3 and RIPK1-mediated induction of NF-
jB but not DAMP release [29,30]. Conversely, another
study demonstrated that immunogenicity of necrop-
totic cells does not correlate with the extent of NF-jB
but rather with DAMP release [27]. Hence, although it
becomes apparent that RIPK1 and RIPK3 are
required for necroptotic cell immunogenicity, the
underlying mechanisms are controversial.
Due to the immunogenic nature of necroptosis,
necroptotic cells have been effectively used to induce
potent antitumor activity and tumor vaccination
[27,29,30]. Consistent with this notion, high expression
levels of RIPK3 in melanoma patients correlated with
improved patient survival [29]. Moreover, RIPK3
expression is lost in many cancer cell lines and in pri-
mary human cancers [27]. Recently, it has been shown
that oncolytic virus-mediated induction of RIPK3
expression in tumor cells conferred durable tumor
clearance and an abscopal effect [29]. Thus, targeting
necroptosis represents an attractive therapeutic
approach in cancer therapy especially in apoptosis-re-
sistant tumors.
2.3. Pyroptosis
Pyroptosis is a lytic pro-inflammatory form of RCD
culminating with the formation of plasma membrane
pores by members of the gasdermin protein family,
primarily gasdermin D (GSDMD), as a consequence
of inflammatory caspase activation (Fig. 1). Inflamma-
tory caspases are comprised of caspase-1, caspase-4,
and caspase-5 in human, and caspase-1 and caspase-11
in mice. Primarily pyroptosis is observed in monocytes
and macrophages but can also occur in epithelial cells
[31,32]. Caspase-1 activation is initiated by ligands of
canonical inflammasomes, which are signaling com-
plexes assembled upon detection of host or pathogen-
derived danger signals (Fig. 1). Instead, cytosolic bac-
terial LPS can directly activate caspase-4 and caspase-
5 in humans or caspase-11 in mice [33]. These caspases
cleave GSDMD liberating an N-terminal fragment
(GSDMDNT), which has intrinsic pore-forming activity
resulting in pyroptosis and the release of DAMPs
(Fig. 1) [31,33]. Caspase-8 can also cleave GSDMD
following apoptotic stimulation [34], whereas GSDME
is cleaved by caspase-3 and caspase-8 to induce pyrop-
tosis either directly or secondary to apoptosis
[31,35,36]. Of note, GSDME is silenced in most can-
cers but expressed in normal tissue. Thus, GSDME-in-
duced pyroptosis has been proposed to underly the
toxicity of chemotherapy drugs [36]. Intriguingly,
restoration of GSDME expression in cancer cells sup-
presses tumor growth mediated by enhancing the
phagocytosis of tumor cells by tumor-associated
macrophages and the activation of tumor-infiltrating
natural killer (NK) and CD8+ T cells [37]. Moreover,
the activation of pyroptosis in tumor cells induces
effective antitumor immunity that synergizes with anti-
PD1 immune checkpoint blockade [38].
Interestingly, the GSDMENT can localize to mito-
chondria and induce MOMP. Likewise, the inflamma-
some-generated GSDMDNT can permeabilize mito-
chondria linking inflammasome activation to apopto-
sis. These data underscore a role of pyroptosis in
inducing MOMP to enhance apoptosis [39]. Active
caspase-1 and caspase-8 process the pro-inflammatory
cytokines interleukin 1b (IL-1b) and IL-18 into their
mature form. Once matured, they are released by
GSDMD and GSDME pores (Fig. 1) [3,40]. Of note,
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the activation of the NLR family, pyrin domain-con-
taining 3 protein (NLRP3) inflammasome, can cause
GSDMD-mediated IL-1 b release from living macro-
phages indicating a nonpyroptotic role of GSDMD
[41].
3. DAMPS: mediators of
immunogenicity
Upon induction of ICD, dying tumor cells release or
expose DAMPs (Fig. 2). Yatim et al. classified
DAMPs as constitutive DAMPs (cDAMPs), which are
immune-stimulatory endogenous molecules that are
constitutively expressed before death and are released
by dying cells, and inducible DAMPs (iDAMPs),
which are the endogenous molecules within dying cells
generated during cell death via mechanisms that are
dependent on the underlying cell death pathway [6].
DAMPs include nucleic acids such as mtDNA detected
by cGAS and stimulator of interferon genes (STING)
pathway, the cell surface exposure of ‘eat me’ signals
such as calreticulin (CRT) and heat-shock proteins
(HSP70 and HSP90) that promote the cell uptake by
APCs, extracellular release of immunostimulatory fac-
tors including adenosine triphosphate (ATP), HMGB1,
and cytokines such as type I IFNs and IL-1 family
(Fig. 2) [2,24,42–44].
Of note, many ICD inducers induce multiple
DAMPs, for example, anthracyclines, radiotherapy,
and Hyp-PDT provoke ICD via inducing the surface
exposure of CRT and HSPs, the secretion of ATP and
HMGB1, and the release of mtDNA that stimulates
the production of type I IFNs (Fig. 2) [2].
3.1. Type I IFNs and IL-1 family cytokines
The rapid production of type I IFNs contributes to
the anticancer effects of certain chemotherapeutics
[45]. Cancer cells succumbing to ICD produce type I
IFNs through the activation of TLR3 by self-RNA
emitted from dying cells [45] or the cGAS/STING
pathway in response to mtDNA release [46]. Hence,
the degradation of extracellular nucleic acids that
result in their reduced sensing by phagocytes such as
DCs, neutrophils, and macrophages, considerably lim-
its the immunogenicity of RCD. Type I IFNs mediate
broad immunostimulatory effects on the aforemen-
tioned immune cells [1]. Additionally, by binding to
IFN-a and IFN-b receptors (IFNAR I) on cancer
cells, type I IFNs trigger autocrine and paracrine sig-
naling pathways culminating in the expression and
release of IFN-stimulated genes (ISGs) including the
T-cell chemoattractant chemokine C-X-C motif ligand
10 (CXCL10). Therefore, tumors lacking Tlr3 or Ifnar
I failed to respond to chemotherapy [45]. Moreover, a
type I IFN-related signature predicted clinical
responses to anthracycline-based chemotherapy and
correlated with improved survival in patients with
breast carcinoma characterized by poor prognosis
[45,47].
Members of the IL-1 cytokine family are powerful
iDAMPs. These cytokines interact with surface recep-
tors expressed in wide range of cells, including
immune, endothelial, and epithelial cells [44]. All these
cell types can produce and secrete IL-1 cytokines in
response to infection, trauma, or NF-kB activation to
stimulate various immune responses. Therefore, the
Fig. 2. Characteristics of immunogenic cell death. When tumor cells succumb to immunogenic cell death (ICD) for example following
radiotherapy, they release or expose damage-associated molecular patterns (DAMPs) that stimulate antitumor immune responses. Tumor
cells expose the endoplasmic reticulum protein calreticulin (CRT) on their plasma membrane in the pre-apoptotic stage. They might also
expose heat-shock proteins (HSPs). These factors facilitate the uptake of dying cells by phagocytes. Additionally, tumor cells responding to
ICD inducer release adenosine triphosphate (ATP) and the nuclear protein high-mobility group box-1 (HMGB1) in the extracellular space.
Mitochondrial outer membrane permeabilization enables the release of mitochondrial DNA (mtDNA) into the cytosol.
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IL-1 cytokine family appears to act as one of the last
signals that alerts the immune system for the presence
of dying cells [3]. An accumulating body of evidence
suggests that various stimuli that induce inflammatory
responses to necrotic cell death act through releasing
IL-1 family members, including ATP. Administration
of purified IL-1 family cytokines in vivo is capable of
promoting the synthesis and secretion of numerous
additional cytokines and chemokines to promote
phagocyte recruitment and the production of inflam-
matory responses [44]. In line with this notion, neutral-
izing antibodies to IL-1 receptor or IL-1b blunt the
therapeutic response of tumors to chemotherapy
in vivo by reducing T-cell priming [43]. Consistently,
IL-1a has been shown to enhance the antitumor effi-
cacy of the epidermal growth factor inhibitor, cetux-
imab, in head and neck squamous cell carcinoma
patients [48].
3.2. Calreticulin
Calreticulin (CRT) is a soluble protein in the lumen of
the ER where it mediates several functions. Those
include chaperone activity and the regulation of cal-
cium homeostasis and signaling, proper assembly of
major histocompatibility complex (MHC) class I mole-
cules, and the loading of antigen. Surface exposure of
CRT is an important ‘eat me’ signal that interacts with
CD91 receptors in phagocytes and enables them to
efficiently engulf dead cells [5,49]. In the course of
ICD, CRT translocation from the ER occurs before
phosphatidyl serine (PS) exposure. This early, pre-
apoptotic exposure of CRT on the plasma membrane
facilitates the uptake of dying cells by DCs, which lead
to subsequent tumor antigen cross-presentation and
tumor-specific cytotoxic T lymphocyte responses [24].
Consistent with a role of CRT in mediating immuno-
genicity of ICD, knockdown of CRT or defects in
CRT exposure pathway abolishes the ability of dying
cancer cells succumbing to anthracyclines to establish
protective immunity in mice, while the provision of
exogenous CRT confers immunogenicity of otherwise
nonimmunogenic types of RCD. Accordingly, CRT
exposure has been shown to have a positive prognostic
value in patients with acute myeloid leukemia [1].
3.3. ATP
Extracellular ATP released from dying cells acts as a
‘find me’ signal and is required for the generation of
robust chemotherapy-induced antitumor immune
responses. Consequently, ATP depletion abolishes the
immunogenicity of cell death [1,5]. Following cell
death, ATP release can occur secondary to caspase-3-
or caspase-7-mediated activity. Additionally, the opti-
mal release of ATP from dying cells has been shown
to require autophagy. Consequently, genetic or phar-
macological inhibition of autophagy strongly reduces
ATP secretion from dying cancer cells and dampens
their immunogenicity [49]. Following chemotherapy,
ATP released is sensed by purinergic P2RX7 receptors
on DCs and induces their recruitment. ATP also medi-
ates immunostimulatory effects by activating the
NLRP3 inflammasome and the subsequent secretion of
IL-1b. This step is mandatory for the DC-mediated
immunogenicity of cell death. Hence, oxaliplatin-trea-
ted tumor cells failed to prime T cells for IFN-c pro-
duction when they were inoculated into P2rx7
receptor-deficient hosts. Furthermore, anthracycline-
treated breast cancer patients carrying a loss-of-func-
tion allele of P2RX7 developed metastatic disease
more rapidly than individuals carrying the normal
allele [43].
3.4. HMGB1
HMGB1 is an abundant nuclear nonhistone chro-
matin-binding protein. An important characteristic of
ICD is the release of HMGB1 from the nucleus into
the surroundings of dying cells (Fig. 2). HMGB1
mediates potent pro-inflammatory effects by binding
to TLR4 on DCs to stimulate efficient processing and
cross-presentation of tumor antigens from dying cells
[43,50]. In a tumor vaccination mouse model, using
HMGB1-depleted tumor cells or neutralizing HMGB1
by specific antibodies compromised the ability of mice
to resist tumorigenesis. Furthermore, breast cancer
patients with a TLR4 loss-of-function allele, that pre-
vents HMGB1 binding to TLR4, are more prone to
relapse after radiotherapy or chemotherapy [50].
Besides, another study indicated that HMGB1 syner-
gizes with ATP to induce IL-1b release by DCs and
that antibody specific for HMGB1 abrogated the abil-
ity of DCs to produce IL-1b in contact with dying
tumor cells [43]. Taken altogether, these observations
delineate an important role of HMGB1 for cell death
immunogenicity. However, accumulating evidence
shows that the immunogenic properties of HMGB1
are dependent upon its redox state. This has been
shown by the potent pro-inflammatory activities of
HMGB1-reduced form in contrast to the inactive oxi-
dized form [51]. Thereby, caspase-dependent produc-
tion of ROS that triggers the oxidation of HMGB1
has been shown to dampen its immunostimulatory
activity leading to the induction of immunological tol-
erance of dying cells [19]. In marked contrast, one
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study has shown that HMGB1 interacted with tumor-
infiltrating DCs to suppress nucleic acid-mediated anti-
tumor activity in mice with established tumors [52].
Nevertheless, since this immunosuppressive effect of
HMGB1 is observed in established tumors where the
tumor environment is likely to contain high levels of
ROS [53], it could be that the inactive oxidized form
of HMGB1 is responsible for the observed tolerogenic
effects in this scenario.
3.5. HSPs
Intracellular HSPs are highly conserved proteins that
have strong cytoprotective and anti-apoptotic proper-
ties. They behave as molecular chaperones for other
cellular proteins [54]. One of the first reports that
described the role of immunogenicity of cell death in
the efficacy of anticancer therapy emerged from the
observation that induction of HSP expression in
response to cell death increased tumor cell immuno-
genicity and conferred enhanced clearance of tumors
in vivo [55]. Subsequent studies demonstrated the cell
surface exposure of HSP70 following Hyp-PDT [23]
and HSP90 after chemotherapy leading to an anti-
cancer immune response [56]. Thus, blocking HSP90
abolished chemotherapy-mediated antitumoral vacci-
nation [56]. Furthermore, the chemotherapy-induced
increased surface expression of HSP70 and HSP90 in
dying tumor cells correlated with DC activation. How-
ever, this DC activation induced by chemotherapy was
completely abolished upon pretreatment of these
tumor cells with neutralizing antibodies against the
HSP70 and HSP90 and CRT common receptor, CD91
[57].
4. Endoplasmic reticulum (ER) stress
and ICD induction
A proposed shared characteristic of ICD inducers is
their ability to induce ER stress and ROS production
[2]. Hence, the more focused the ER stress is, the
higher the immunogenicity of cell death is. On this
basis, ICD inducers have been classified into type I
ICD inducers that prompt secondary or collateral ER
stress such as anthracyclines and radiotherapy and
type II ICD inducers that foster focused ROS-based
ER stress including hypericin-based photodynamic
therapy (Hyp-PDT) and oncolytic viruses, with the lat-
ter being more immunogenic [2,5]. The first systematic
screening for ICD inducers identified the anthracycline
doxorubicin as efficient inducer through its ability to
induce ER stress [24]. Supporting this notion, con-
comitant induction of ER stress restores the
immunogenicity of poor ICD inducer chemotherapeu-
tics such as cisplatin [58], etoposide, and mitomycin C
[24]. The importance of ROS was evident by the
diminished immunogenicity of ICD in the presence of
antioxidants [5]. Importantly, ROS-mediated ER stress
induced by Hyp-PDT has been shown to induce the
emission of multiple DAMPs ultimately leading to
protective antitumor immune responses [42]. This is
because hypericin is an ER-localizing drug that causes
massive production of ROS at the ER when excited by
light of a specific wavelength leading to focused ROS-
based ER stress [5].
5. T-cell priming and antitumor
immune responses following ICD
The innate immune system plays a crucial role in the
activation of adaptive immunity leading to tumor-
specific immune responses. Consistent with this, har-
nessing innate immunity has proven to be highly effec-
tive in controlling tumor growth and promoting
responses to immune checkpoint inhibitors, that
unleash effector T cells, in a variety of preclinical and
clinical studies (reviewed in ref. [59]). Following ICD,
DAMPs stimulate PRRs on macrophages, DCs, and
NK cells leading to T-cell activation and the initiation
of immune responses [6]. In order for cell death to
provoke an immune response, the dying cell needs to
trigger a total of five steps (Fig. 3). The cell death
event itself is considered signal 1, while the release of
DAMPs and their recognition by PRRs constitutes sig-
nal 0 [3,6]. DAMPs mediate the attraction of phago-
cytes that engulf and process dying cells to present
their antigens on the surface of antigen-presenting cells
such as DCs (Fig. 3). Activated DCs migrate to drain-
ing lymphoid organs where they maturate and encoun-
ter naive T cells [3,6,60]. Signal 1 comprises antigen
recognition mediated through the T-cell receptor and
trigged by DCs cross-presentation of tumor antigens
on MHC I or MHC II molecules to CD8+ T cells and
CD4+ T cells, respectively (Fig. 3). Efficient T-cell acti-
vation requires the engagement of naive T cells with
co-stimulatory receptors on DCs such as CD80 and
CD86 (signal 2). Signal 3 is the additional polarization
and differentiation signals delivered from DCs, includ-
ing IL-12 or type I IFNs, that are crucial for T-cell
differentiation into a T-cell effector. All these events
eventually lead to priming of tumor-specific CD8+ T
cells (Fig. 3) [3,6,59].
Noteworthy, although DAMPs such as ATP and
HMGB1 induce DC maturation and provoke cytokine
release, they are insufficient for the induction of effec-
tive T-cell cross-priming highlighting the need for
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further signals [30]. Phagocytes are attracted by ‘find
me’ signals that are released by dying cells including
ATP and NF-jB-induced signals that trigger phago-
cyte infiltration. Once phagocytes reach the site of tis-
sue damage, they recognize ‘eat me’ signals on the
surface of dying cells such as PS. In contrast, the sur-
face of healthy cells displays ‘don’t eat me’ signals,
such as CD47 [6]. Consistently, increased CD47
expression on tumor cells prevents DNA sensing in
DCs leading to immune evasion. Thus, the inhibition
of CD47 enhances tumor antigen sensing by DCs elic-
iting effective T-cell priming and tumor rejection in
mice [60].
As discussed earlier, the therapeutic efficacy of
anticancer chemotherapies largely depends on DCs,
which present antigens from dying cancer cells to
prime tumor-specific IFN-c-producing T lymphocytes
(Fig. 3) [43,60]. Dying tumor cells release ATP, which
activates the NLRP3 inflammasome in DCs allowing
for the secretion of IL-1b, a cytokine which is
required for the polarization of IFN-c-producing
CD8+ T cells. Therefore, the priming of IFN-c-pro-
ducing CD8+ T cells by dying tumor cells fails in the
absence of a functional IL-1 receptor 1 and in Nlrp3-
deficient or caspase-1-deficient mice unless exogenous
IL-1b is provided. Consistent with this finding,
tumors established in Nlrp3-deficient or caspase-1-de-
ficient hosts were not effectively targeted by
chemotherapy [43]. In summary, robust antitumor
immune responses require the efficient priming of
tumor antigen-specific IFN-c-producing CD8+ T cells
that mediate tumor clearance.
6. Inflammatory pathways activated
during ICD
The NF-jB pathway regulates diverse cellular pro-
cesses including proliferation and cell survival, cyto-
kine production, antipathogen response, and
inflammation. NF-jB is tightly connected to decisions
of life and death, particularly during extrinsic apopto-
sis and necroptosis [3,13]. In the context of ICD,
Fig. 3. Role of DAMPs in antigen cross-priming and antitumor immune responses. Upon immunogenic cell death (ICD) induction, dying
tumor cells release tumor antigen and damage-associated molecular patterns (DAMPs). DAMPs stimulate pattern recognition receptors
(PRRs) on dendritic cells (DCs) leading to T-cell activation and the initiation of tumor-specific antitumor immune responses following five
signals (signals 1 to 3). Signal 1 is the cell death process itself that results in DAMPs and provides tumor antigens for antigen cross-
priming. DAMPs mediate the attraction and activation of DCs that engulf and process dying cells (signal 0). DCs provide 3 signals to
activate T cells; signal 1 is the antigen recognition mediated through the T-cell receptor (TCR), trigged by DCs cross-presentation of tumor
antigens on major histocompatibility complex (MHC) I or MHC II molecules to CD8+ T cells and CD4+ T cells, respectively. Signal 2 is the
engagement of naive T cells with co-stimulatory receptors on DCs such as CD80 which is required for efficient T-cell activation. Signal 3 is
the additional polarization and differentiation signals delivered from DCs, including interleukin 12 (IL-12) or type I interferons (IFNs), that are
crucial for T-cell differentiation into tumor-specific IFN-c-producing T cells.
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uncoupling cell death from NF-jB activation dampens
the pro-inflammatory response elicited by dying cells
and leads to inefficient CD8+ T-cell priming [14,30].
Supporting this notion, robust CD8+ T-cell cross-prim-
ing has been shown to critically require active RIPK1
and NF-jB signaling within dying cells, but not the
DAMPs released by these cells [30]. Nonetheless, how
NF-jB activation within dying cells actively regulates
cross-priming is unknown [6].
The presence of cytosolic DNA either through bac-
terial or viral infections or cellular damage triggers
robust pro-inflammatory immune responses [61]. Nota-
bly following MOMP, the release of mtDNA into the
cytosol activates a plethora of innate immune
responses, including cGAS-STING that triggers type I
IFN responses (Fig. 4), TLR9 which activates NF-jB,
and inflammasome formation leading to pyroptosis
and the maturation of IL-1b and IL-18 (reviewed in
ref. [46]). Cytosolic DNA activates cGAS to form a
dimeric cGAS-DNA complex, which synthesizes cyclic
guanosine monophosphate–adenosine monophosphate
(cGAMP) from ATP and GTP (Fig. 4). cGAMP in
turn binds and activates the ER membrane protein
STING that subsequently recruits TANK-binding
kinase 1 (TBK1). TBK1 phosphorylates and activates
the transcription factors IRF3 and NF-jB, leading to
the production of type I IFNs and other cytokines
(Fig. 4) [46,61]. Accumulating evidence demonstrated
that apoptotic caspase activity dampens the produc-
tion of mtDNA-induced type I IFNs [16–18],
implicating a therapeutic potential for caspase inhibi-
tion in cancer therapy. Supporting this idea, engaging
MOMP under caspase-inhibited conditions results in
activation of NF-jB-mediated upregulation of cytoki-
nes and chemokines that promotes activation of anti-
tumorigenic macrophage and cytotoxic CD8+ T cells
leading to robust antitumor immune responses culmi-
nating in tumor regression [14]. Likewise, a recent
study showed that concomitant treatment of mice with
caspase inhibitor and radiation results in robust antitu-
mor immune responses as a consequence of enhanced
tumor-derived mtDNA-mediated production of type I
IFNs [20].
Type I IFNs have long been used for the effective
treatment of multiple cancers even before their mecha-
nism of action was known and proposed to be utilized
as adjuvant to cancer vaccines [62]. The importance of
type I IFNs in mediating antitumor immune responses
is evidenced by the fact that blocking type I IFNs and
the deficiency of IFNAR I abrogates tumor rejection
[63]. Type I IFNs stimulate the activation of DCs fol-
lowing engulfment of apoptotic tumor cells, sustain
tumor antigen-bearing DCs survival, and enhance anti-
gen cross-presentation leading to CD8+ T-cell cross-
priming [64]. The rapid induction of type I IFNs in
tumor cells underlines the mechanism of ICD follow-
ing anthracycline treatment of multiple cancer cell
lines. This effect required signaling via IFNAR I for
efficient antitumor immunity [45]. Similarly, the
cGAS-STING-IRF3-type I IFN cascade mediates a
Fig. 4. cGAS-STING signaling pathway. The presence of cytosolic DNA either through bacterial or viral infections or cellular damage leading
to mitochondrial outer membrane permeabilization (MOMP)-induced mitochondrial DNA (mtDNA) release activates cyclic GMP-AMP
synthase (cGAS). Activated cGAS forms a dimeric cGAS-DNA complex, which synthesizes cyclic guanosine monophosphate–adenosine
monophosphate (cGAMP) from ATP and GTP. cGAMP binds to and activates the endoplasmic reticulum (ER) membrane protein, stimulator
of interferon genes (STING), that subsequently recruits TANK-binding kinase 1 (TBK1). TBK1 phosphorylates and activates the transcription
factor interferon regulatory factor 3 (IRF3) leading to the production of type I interferons.
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robust antitumor effects following radiation [65]. Thus,
enhancing cGAS-STING signaling leading to type I
IFN production represents a promising therapeutic
approach for cancer treatment.
7. Conclusions and perspectives
The concept of cancer immunotherapy is to harness
the immune system to elicit antitumor immune
response. Accumulating evidence clearly underscored
the ability of DAMPs released from dying cells to acti-
vate specific antitumor immune responses. Under-
standing the molecular pathways by which certain
cancer therapeutics induce DAMPs and activate the
host immune system offer the potential to convert
nonimmunogenic inducers of cell death to potent ICD
inducers and open the prospect for improving tumor
vaccination strategy. Despite tremendous efforts aim-
ing to characterize ICD, the current knowledge is far
from being established. Outstanding questions exist:
What makes a certain cell death modality immuno-
genic? Similarly, what are the factors affecting the
immunogenicity of a dying cell? Additionally, since
most of the ICD research is conducted in cancer cells
and tumor vaccination models, it would be of utmost
importance to test ICD in more advanced tumor mod-
els such as orthotopic and genetically engineered
mouse models to reflect the complexity of human dis-
ease. Noteworthy, although ICD has been shown in
several preclinical models, evidence for ICD in human
patients is less compelling. Therefore, further research
in human patients is needed to investigate the potential
of ICD in clinical settings. Notably, identifying
biomarkers that stratify patients according to their
benefit from ICD immunotherapy would be of great
advantage. Furthermore, it is tempting to speculate
that the administration of single or multiple ICD
inducers, in addition to harnessing innate immunity
and/or immune checkpoint inhibition, is likely to boost
the antitumor immune responses resulting in abscopal
effect conferring long-term systemic protection from
cancer development. Nevertheless, these assumptions
remain to be tested as the ICD field is actively expand-
ing and special consideration of the dosage and treat-
ment regiments must be kept in mind to avoid
toxicities and the emergence of resistance.
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